Pilot Pharmacokinetic and Dosimetric Studies of 18F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging αvβ3 Integrin Levels
Abstract
The radiopharmaceutical agent 18F-FPPRGD2 has desirable pharmacokinetic and biodistribution properties, with the latter favoring PET applications in the head, neck, thorax, and extremities.
Purpose
To assess the safety, biodistribution, and dosimetric properties of the positron emission tomography (PET) radiopharmaceutical agent fluorine 18 (18F) FPPRGD2 (2-fluoropropionyl labeled PEGylated dimeric RGD peptide [PEG3-E{c(RGDyk)}2]), which is based on the dimeric arginine-glycine–aspartic acid (RGD) peptide sequence and targets αvβ3 integrin, in the first volunteers imaged with this tracer.
Materials and Methods
The protocol was approved by the institutional review board, and written informed consent was obtained from all participants. Five healthy volunteers underwent whole-body combined PET–computed tomography 0.5, 1.0, 2.0, and 3.0 hours after tracer injection (mean dose, 9.5 mCi ± 3.4 [standard deviation] [351.5 MBq ± 125.8]; mean specific radioactivity, 1200 mCi/mmol ± 714 [44.4 GBq/mmol ± 26.4]). During this time, standard vital signs, electrocardiographic (ECG) readings, and blood sample values (for chemistry, hematologic, and liver function tests) were checked at regular intervals and 1 and 7 days after the injection. These data were used to evaluate tracer biodistribution and dosimetric properties, time-activity curves, and the stability of laboratory values. Significant changes in vital signs and laboratory values were evaluated by using a combination of population-averaged generalized estimating equation regression and exact paired Wilcoxon tests.
Results
The administration of 18F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values. The tracer showed the same pattern of biodistribution in all volunteers: primary clearance through the kidneys (0.360 rem/mCi ± 0.185 [0.098 mSv/MBq ± 0.050]) and bladder (0.862 rem/mCi ± 0.436 [0.233 mSv/MBq ± 0.118], voiding model) and uptake in the spleen (0.250 rem/mCi ± 0.168 [0.068 mSv/MBq ± 0.046]) and large intestine (0.529 rem/mCi ± 0.236 [0.143 mSv/MBq ± 0.064]). The mean effective dose of 18F-FPPRGD2 was 0.1462 rem/mCi ± 0.0669 (0.0396 mSv/MBq ± 0.0181). With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding interval, a patient would be exposed to an effective radiation dose of 1.5 rem (15 mSv). Above the diaphragm, there was minimal uptake in the brain ventricles, salivary glands, and thyroid gland. Time-activity curves showed rapid clearance from the vasculature, with a mean 26% ± 17 of the tracer remaining in the circulation at 30 minutes and most of the activity occurring in the plasma relative to cells (mean whole blood–plasma ratio, 0.799 ± 0.096).
Conclusion
18F-FPPRGD2 has desirable pharmacokinetic and biodistribution properties. The primary application is likely to be PET evaluation of oncologic patients—especially those with brain, breast, or lung cancer. Specific indications may include tumor staging, identifying patients who would benefit from antiangiogenesis therapy, and separating treatment responders from nonresponders early.
© RSNA, 2011
Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11101139/-/DC1
References
- 1 . Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1–8.
- 2 . Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15–18.
- 3 . Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100(12):2491–2499.
- 4 . Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9(1):355–362.
- 5 . Role of alpha v integrins during angiogenesis. Cancer J 2000;6(Suppl 3):S245–S249.
- 6 . Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98(4):1853–1858.
- 7 . The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002;11(12):1765–1774.
- 8 . Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10(13):1439–1455.
- 9 . Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008;249(1):212–219.
- 10 . Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010;51(3):433–440.
- 11 . Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248(3):936–944.
- 12 . US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008;246(2):508–518.
- 13 . Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4(5):623–626.
- 14 . In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004;64(21):8009–8014.
- 15 . Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 2004;3(4):343–351.
- 16 . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2(9):683–693.
- 17 . [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15(1):61–69.
- 18 . Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61(5):1781–1785.
- 19 . Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005;2(3):e70.
- 20 . Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 2004;45(10):1776–1783.
- 21 . MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31(8):1081–1089.
- 22 . Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett 2004;14(1):211–215.
- 23 . A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin. Science 1998;280(5364):708–711.
- 24 . (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 2008;35(6):1100–1108.
- 25 . Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem 2007;18(6):1987–1994.
- 26 . MicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007;48(9):1536–1544.
- 27 . (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48(7):1162–1171.
- 28 . 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34(11):1823–1831.
- 29 . 18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol 2010;12(5):530–538.
- 30 . Initial experience with clinical-grade [18F]FPP(RGD)2: an automated multi-step radiosynthesis for clinical PET studies. J Nucl Med (in press).
- 31 . First experience with clinical-grade [18F]FPP (RGD)2: an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol.
- 32 . OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023–1027.
- 33 International Commission on Radiological Protection. Radiation protection in medicine. ICRP publication 105. Ann ICRP 2007;37(6):1–63.
- 34 International Commission on Radiological Protection. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1–332.
- 35 . Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008;27(4):631–644.
- 36 . Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosimetry 2010;139(1-3):208–213.
- 37 . The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49(10):1664–1667.
- 38 . Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008;78(2):395–403.
Article History
Received June 7, 2010; revision requested August 2; revision received December 29; accepted January 18, 2011; final version accepted February 14.Published online: July 2011
Published in print: July 2011